Who are Vitamin B12 Coenzyme's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cystadane, EnBrace HR, Decitabine and cedazuridine, Vitamin Q, Decitabine plus HAAG regimen, VEN combined with azacitidine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cobamamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Vitamin B12 Coenzyme — Competitive Intelligence Brief

Vitamin B12 Coenzyme (COBAMAMIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Methylating Agent [EPC]. Area: Metabolic.

marketed Methylating Agent [EPC] Metabolic Live · refreshed every 30 min

Target snapshot

Vitamin B12 Coenzyme (COBAMAMIDE). Vitamin B12 Coenzyme (COBAMAMIDE) works by providing the body with a necessary coenzyme for various metabolic processes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vitamin B12 Coenzyme TARGET	COBAMAMIDE		marketed	Methylating Agent [EPC]
Cystadane	BETAINE	Recordati	marketed	Methylating Agent [EPC]		1996-01-01
EnBrace HR	COCARBOXYLASE	Jaymac Pharmaceuticals, LLC	marketed	Methylating Agent [EPC]
Decitabine and cedazuridine	Decitabine and cedazuridine	Race Oncology Ltd	marketed	Hypomethylating agent	DNA methyltransferase (DNMT)
Vitamin Q	UBIDECARENONE		marketed	Methylating Agent [EPC]
Decitabine plus HAAG regimen	Decitabine plus HAAG regimen	The First Affiliated Hospital of Soochow University	phase 3	Hypomethylating agent combined with chemotherapy regimen	DNA methyltransferase (DNMT)
VEN combined with azacitidine	VEN combined with azacitidine	Nanfang Hospital, Southern Medical University	phase 3	Hypomethylating agent and histone deacetylase inhibitor	DNA methyltransferase and histone deacetylase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Methylating Agent [EPC] class)

· 2 drugs in this class
Jaymac Pharmaceuticals, LLC · 1 drug in this class
Recordati · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vitamin B12 Coenzyme — Competitive Intelligence Brief. https://druglandscape.com/ci/cobamamide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab